This, combined with conflicting data on its oncogenicity and the classification of germline MET R970C as a variant of uncertain significance (VUS) in various ClinVar submissions, highlights the need for further investigations, including functional assays and patient cohort studies, to elucidate its precise involvement in the progression and therapy resistance of NB. The gene discussed is MET; the disease is neuroblastoma.